Currently Viewing:
NCCN 2016

Dr Pamela Becker Says the US Is "Just Scratching the Surface" for Biosimilars

Now that 1 biosimilar has made it to market in the United States, Pamela S. Becker, MD, PhD, professor of medicine in the Division of Hematology at the University of Washington School of Medicine, expects more to follow and that, hopefully, biosimilars will help achieve cost savings for healthcare.


Now that 1 biosimilar has made it to market in the United States, Pamela S. Becker, MD, PhD, professor of medicine in the Division of Hematology at the University of Washington School of Medicine, expects more to follow and that, hopefully, biosimilars will help achieve cost savings for healthcare.

Transcript (slightly modified)

Do you foresee a smoother transition for the biosimilar market in the US going forward?

I think that since there has now been precedence now that the biosimilar pathway to approval has been tested and successfully implemented, I think that will enable other drugs to achieve approval via the biosimilar pathway.

I think we're only just scratching the surface. I think there will be many more biosimilars coming into the marketplace and hopefully the cost reduction that was perceived and part of the motivation for developing the biosimilar approval process, hopefully, those cost savings will be realized for healthcare.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!